Australia markets closed

ZYUS Life Sciences Corporation (ZYUS.V)

TSXV - TSXV Real-time price. Currency in CAD
Add to watchlist
1.0000-0.0200 (-1.96%)
At close: 11:59AM EST
Full screen
Previous close1.0200
Open1.0000
Bid0.9900 x N/A
Ask1.0000 x N/A
Day's range1.0000 - 1.0000
52-week range0.7100 - 2.5000
Volume300
Avg. volume10,028
Market cap69.847M
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)-0.3500
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Business Wire

    ZYUS Strengthens Expertise of Clinical Advisory Committee with the Appointment of Dr. Hance Clarke

    SASKATOON, Saskatchewan, February 01, 2024--ZYUS Life Sciences Corporation (the "Company") (TSX-V: ZYUS), a Canadian-based life sciences company leading scientific research and global development of innovative cannabinoid-based pharmaceutical drug products, today announced the appointment of Hance Clarke, MD, PhD, FRCPC to ZYUS Life Sciences Inc.’s Clinical Advisory Committee. Dr. Clarke’s extensive background in healthcare and pain management aligns seamlessly with the committee's mission to pr

  • GlobeNewswire

    Presenting on the Emerging Growth Conference 66 Day 1 on January 10 Register Now

    MIAMI, Jan. 09, 2024 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 66th Emerging Growth Conference on January 10 & 11, 2024. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting comp

  • Business Wire

    ZYUS Strengthens Leadership Team with Appointment of Vice President of Clinical Research

    SASKATOON, Saskatchewan, January 09, 2024--ZYUS Life Sciences Corporation (the "Company") (TSX-V: ZYUS), a Canadian-based life sciences company leading scientific research and global development of innovative cannabinoid-based pharmaceutical drug products, today announced that it has strengthened its leadership team with the appointment of Scott Livingstone to the role of Vice President of Clinical Research with its wholly owned subsidiary, ZYUS Life Sciences Inc. In this instrumental role, Mr.